Free Trial
NASDAQ:JBIO

Jade Biosciences (JBIO) Stock Price, News & Analysis

Jade Biosciences logo
$7.58 -0.03 (-0.39%)
As of 10:38 AM Eastern

About Jade Biosciences Stock (NASDAQ:JBIO)

Advanced

Key Stats

Today's Range
$7.58
$7.88
50-Day Range
$6.77
$9.51
52-Week Range
$6.57
$105.00
Volume
3,161 shs
Average Volume
153,488 shs
Market Capitalization
$247.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
Consensus Rating
Buy

Company Overview

Jade Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

JBIO MarketRank™: 

Jade Biosciences scored higher than 34% of companies evaluated by MarketBeat, and ranked 760th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Jade Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Jade Biosciences has a consensus price target of $16.00, representing about 110.2% upside from its current price of $7.61.

  • Amount of Analyst Coverage

    Jade Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Jade Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Jade Biosciences is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Jade Biosciences is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Jade Biosciences has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.49% of the float of Jade Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Jade Biosciences has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

  • Dividend Yield

    Jade Biosciences does not currently pay a dividend.

  • Dividend Growth

    Jade Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.49% of the float of Jade Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Jade Biosciences has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

  • Search Interest

    12 people have searched for JBIO on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Jade Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.90% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Jade Biosciences' insider trading history.
Receive JBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JBIO Stock News Headlines

IRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
Jade Biosciences Reports Q2 2025 Financial Results
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences Posts Wider Loss in Q2
See More Headlines

JBIO Stock Analysis - Frequently Asked Questions

Jade Biosciences' stock was trading at $7.06 at the beginning of the year. Since then, JBIO shares have increased by 7.8% and is now trading at $7.61.

Jade Biosciences, Inc. (NASDAQ:JBIO) announced its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.43.

Jade Biosciences' top institutional shareholders include Frazier Life Sciences Management L.P. (210.97%), Versant Venture Management LLC (181.43%), Soleus Capital Management L.P. (94.85%) and Geode Capital Management LLC (80.43%).

Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/13/2025
Today
9/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:JBIO
Previous Symbol
NASDAQ:JBIO
CIK
1798749
Web
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$14.00
Potential Upside/Downside
+110.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($30.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.63 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-51.96%
Return on Assets
-47.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.31
Quick Ratio
10.31

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$92.88 per share
Price / Book
0.08

Miscellaneous

Outstanding Shares
32,627,000
Free Float
24,503,000
Market Cap
$248.29 million
Optionable
N/A
Beta
1.04
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:JBIO) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners